Merck Presents Results of a Phase I Clinical Trial Evaluating Investigational BACE inhibitor MK-8931 at American Academy of ...
WHITEHOUSE STATION N.J., April 27, 2012 - Merck, known as MSD outside the United States and Canada, today presented Phase I data evaluating the safety and tolerability of its novel, oral β-amyloid precursor protein site cleaving enzyme (BACE) inhibitor, MK …